nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—prostate cancer—urinary bladder cancer	0.862	1	CtDrD
Goserelin—LHCGR—renal system—urinary bladder cancer	0.000833	0.432	CbGeAlD
Goserelin—LHCGR—female reproductive system—urinary bladder cancer	0.000667	0.346	CbGeAlD
Goserelin—GNRHR—female reproductive system—urinary bladder cancer	0.00043	0.223	CbGeAlD
Goserelin—Gastrointestinal pain—Etoposide—urinary bladder cancer	7.37e-05	0.00054	CcSEcCtD
Goserelin—Pruritus—Fluorouracil—urinary bladder cancer	7.34e-05	0.000538	CcSEcCtD
Goserelin—Drowsiness—Doxorubicin—urinary bladder cancer	7.33e-05	0.000537	CcSEcCtD
Goserelin—Hypersensitivity—Cisplatin—urinary bladder cancer	7.25e-05	0.000531	CcSEcCtD
Goserelin—Diarrhoea—Gemcitabine—urinary bladder cancer	7.22e-05	0.000529	CcSEcCtD
Goserelin—Renal failure—Doxorubicin—urinary bladder cancer	7.2e-05	0.000528	CcSEcCtD
Goserelin—Urticaria—Etoposide—urinary bladder cancer	7.16e-05	0.000525	CcSEcCtD
Goserelin—Haemoglobin—Epirubicin—urinary bladder cancer	7.14e-05	0.000524	CcSEcCtD
Goserelin—Jaundice—Doxorubicin—urinary bladder cancer	7.14e-05	0.000523	CcSEcCtD
Goserelin—Rhinitis—Epirubicin—urinary bladder cancer	7.13e-05	0.000522	CcSEcCtD
Goserelin—Abdominal pain—Etoposide—urinary bladder cancer	7.12e-05	0.000522	CcSEcCtD
Goserelin—Body temperature increased—Etoposide—urinary bladder cancer	7.12e-05	0.000522	CcSEcCtD
Goserelin—Urinary tract infection—Doxorubicin—urinary bladder cancer	7.12e-05	0.000522	CcSEcCtD
Goserelin—Haemorrhage—Epirubicin—urinary bladder cancer	7.11e-05	0.000521	CcSEcCtD
Goserelin—Hepatitis—Epirubicin—urinary bladder cancer	7.11e-05	0.000521	CcSEcCtD
Goserelin—Eye disorder—Methotrexate—urinary bladder cancer	7.1e-05	0.00052	CcSEcCtD
Goserelin—Diarrhoea—Fluorouracil—urinary bladder cancer	7.1e-05	0.00052	CcSEcCtD
Goserelin—Asthenia—Cisplatin—urinary bladder cancer	7.06e-05	0.000517	CcSEcCtD
Goserelin—Pharyngitis—Epirubicin—urinary bladder cancer	7.06e-05	0.000517	CcSEcCtD
Goserelin—Cardiac disorder—Methotrexate—urinary bladder cancer	7.05e-05	0.000517	CcSEcCtD
Goserelin—Sweating—Doxorubicin—urinary bladder cancer	7.02e-05	0.000515	CcSEcCtD
Goserelin—Urinary tract disorder—Epirubicin—urinary bladder cancer	7.02e-05	0.000514	CcSEcCtD
Goserelin—Oedema peripheral—Epirubicin—urinary bladder cancer	7e-05	0.000513	CcSEcCtD
Goserelin—Haematuria—Doxorubicin—urinary bladder cancer	6.99e-05	0.000512	CcSEcCtD
Goserelin—Urethral disorder—Epirubicin—urinary bladder cancer	6.97e-05	0.000511	CcSEcCtD
Goserelin—Epistaxis—Doxorubicin—urinary bladder cancer	6.91e-05	0.000506	CcSEcCtD
Goserelin—Angiopathy—Methotrexate—urinary bladder cancer	6.89e-05	0.000505	CcSEcCtD
Goserelin—Sinusitis—Doxorubicin—urinary bladder cancer	6.87e-05	0.000504	CcSEcCtD
Goserelin—Immune system disorder—Methotrexate—urinary bladder cancer	6.86e-05	0.000503	CcSEcCtD
Goserelin—Dizziness—Fluorouracil—urinary bladder cancer	6.86e-05	0.000503	CcSEcCtD
Goserelin—Chills—Methotrexate—urinary bladder cancer	6.82e-05	0.000499	CcSEcCtD
Goserelin—Diarrhoea—Cisplatin—urinary bladder cancer	6.73e-05	0.000493	CcSEcCtD
Goserelin—Alopecia—Methotrexate—urinary bladder cancer	6.71e-05	0.000492	CcSEcCtD
Goserelin—Vomiting—Gemcitabine—urinary bladder cancer	6.71e-05	0.000492	CcSEcCtD
Goserelin—Mental disorder—Methotrexate—urinary bladder cancer	6.65e-05	0.000488	CcSEcCtD
Goserelin—Rash—Gemcitabine—urinary bladder cancer	6.65e-05	0.000488	CcSEcCtD
Goserelin—Dermatitis—Gemcitabine—urinary bladder cancer	6.65e-05	0.000487	CcSEcCtD
Goserelin—Eye disorder—Epirubicin—urinary bladder cancer	6.64e-05	0.000487	CcSEcCtD
Goserelin—Hypersensitivity—Etoposide—urinary bladder cancer	6.64e-05	0.000486	CcSEcCtD
Goserelin—Malnutrition—Methotrexate—urinary bladder cancer	6.61e-05	0.000485	CcSEcCtD
Goserelin—Erythema—Methotrexate—urinary bladder cancer	6.61e-05	0.000485	CcSEcCtD
Goserelin—Haemoglobin—Doxorubicin—urinary bladder cancer	6.61e-05	0.000484	CcSEcCtD
Goserelin—Headache—Gemcitabine—urinary bladder cancer	6.61e-05	0.000484	CcSEcCtD
Goserelin—Cardiac disorder—Epirubicin—urinary bladder cancer	6.6e-05	0.000483	CcSEcCtD
Goserelin—Vomiting—Fluorouracil—urinary bladder cancer	6.6e-05	0.000483	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—urinary bladder cancer	6.59e-05	0.000483	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—urinary bladder cancer	6.58e-05	0.000482	CcSEcCtD
Goserelin—Hepatitis—Doxorubicin—urinary bladder cancer	6.58e-05	0.000482	CcSEcCtD
Goserelin—Rash—Fluorouracil—urinary bladder cancer	6.54e-05	0.000479	CcSEcCtD
Goserelin—Dermatitis—Fluorouracil—urinary bladder cancer	6.54e-05	0.000479	CcSEcCtD
Goserelin—Pharyngitis—Doxorubicin—urinary bladder cancer	6.53e-05	0.000478	CcSEcCtD
Goserelin—Headache—Fluorouracil—urinary bladder cancer	6.5e-05	0.000476	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	6.5e-05	0.000476	CcSEcCtD
Goserelin—Oedema peripheral—Doxorubicin—urinary bladder cancer	6.48e-05	0.000475	CcSEcCtD
Goserelin—Asthenia—Etoposide—urinary bladder cancer	6.46e-05	0.000474	CcSEcCtD
Goserelin—Angiopathy—Epirubicin—urinary bladder cancer	6.45e-05	0.000473	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—urinary bladder cancer	6.45e-05	0.000473	CcSEcCtD
Goserelin—Immune system disorder—Epirubicin—urinary bladder cancer	6.42e-05	0.000471	CcSEcCtD
Goserelin—Back pain—Methotrexate—urinary bladder cancer	6.4e-05	0.000469	CcSEcCtD
Goserelin—Chills—Epirubicin—urinary bladder cancer	6.38e-05	0.000467	CcSEcCtD
Goserelin—Pruritus—Etoposide—urinary bladder cancer	6.37e-05	0.000467	CcSEcCtD
Goserelin—Arrhythmia—Epirubicin—urinary bladder cancer	6.35e-05	0.000465	CcSEcCtD
Goserelin—Alopecia—Epirubicin—urinary bladder cancer	6.28e-05	0.00046	CcSEcCtD
Goserelin—Nausea—Gemcitabine—urinary bladder cancer	6.27e-05	0.000459	CcSEcCtD
Goserelin—Vomiting—Cisplatin—urinary bladder cancer	6.25e-05	0.000458	CcSEcCtD
Goserelin—Vision blurred—Methotrexate—urinary bladder cancer	6.23e-05	0.000457	CcSEcCtD
Goserelin—Mental disorder—Epirubicin—urinary bladder cancer	6.23e-05	0.000456	CcSEcCtD
Goserelin—Rash—Cisplatin—urinary bladder cancer	6.2e-05	0.000454	CcSEcCtD
Goserelin—Dermatitis—Cisplatin—urinary bladder cancer	6.2e-05	0.000454	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—urinary bladder cancer	6.19e-05	0.000454	CcSEcCtD
Goserelin—Erythema—Epirubicin—urinary bladder cancer	6.19e-05	0.000454	CcSEcCtD
Goserelin—Diarrhoea—Etoposide—urinary bladder cancer	6.16e-05	0.000452	CcSEcCtD
Goserelin—Nausea—Fluorouracil—urinary bladder cancer	6.16e-05	0.000452	CcSEcCtD
Goserelin—Eye disorder—Doxorubicin—urinary bladder cancer	6.15e-05	0.00045	CcSEcCtD
Goserelin—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.14e-05	0.00045	CcSEcCtD
Goserelin—Anaemia—Methotrexate—urinary bladder cancer	6.11e-05	0.000448	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—urinary bladder cancer	6.1e-05	0.000447	CcSEcCtD
Goserelin—Flatulence—Epirubicin—urinary bladder cancer	6.1e-05	0.000447	CcSEcCtD
Goserelin—Tension—Epirubicin—urinary bladder cancer	6.07e-05	0.000445	CcSEcCtD
Goserelin—Nervousness—Epirubicin—urinary bladder cancer	6.01e-05	0.00044	CcSEcCtD
Goserelin—Back pain—Epirubicin—urinary bladder cancer	5.99e-05	0.000439	CcSEcCtD
Goserelin—Angiopathy—Doxorubicin—urinary bladder cancer	5.97e-05	0.000437	CcSEcCtD
Goserelin—Malaise—Methotrexate—urinary bladder cancer	5.96e-05	0.000437	CcSEcCtD
Goserelin—Dizziness—Etoposide—urinary bladder cancer	5.96e-05	0.000437	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—urinary bladder cancer	5.95e-05	0.000436	CcSEcCtD
Goserelin—Immune system disorder—Doxorubicin—urinary bladder cancer	5.94e-05	0.000435	CcSEcCtD
Goserelin—Leukopenia—Methotrexate—urinary bladder cancer	5.92e-05	0.000434	CcSEcCtD
Goserelin—Chills—Doxorubicin—urinary bladder cancer	5.9e-05	0.000433	CcSEcCtD
Goserelin—Arrhythmia—Doxorubicin—urinary bladder cancer	5.88e-05	0.000431	CcSEcCtD
Goserelin—Nausea—Cisplatin—urinary bladder cancer	5.84e-05	0.000428	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—urinary bladder cancer	5.83e-05	0.000427	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—urinary bladder cancer	5.81e-05	0.000426	CcSEcCtD
Goserelin—Cough—Methotrexate—urinary bladder cancer	5.77e-05	0.000423	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—urinary bladder cancer	5.76e-05	0.000422	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—urinary bladder cancer	5.74e-05	0.000421	CcSEcCtD
Goserelin—Convulsion—Methotrexate—urinary bladder cancer	5.73e-05	0.00042	CcSEcCtD
Goserelin—Vomiting—Etoposide—urinary bladder cancer	5.73e-05	0.00042	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—urinary bladder cancer	5.73e-05	0.00042	CcSEcCtD
Goserelin—Erythema—Doxorubicin—urinary bladder cancer	5.73e-05	0.00042	CcSEcCtD
Goserelin—Anaemia—Epirubicin—urinary bladder cancer	5.72e-05	0.000419	CcSEcCtD
Goserelin—Rash—Etoposide—urinary bladder cancer	5.68e-05	0.000416	CcSEcCtD
Goserelin—Dermatitis—Etoposide—urinary bladder cancer	5.68e-05	0.000416	CcSEcCtD
Goserelin—Headache—Etoposide—urinary bladder cancer	5.64e-05	0.000414	CcSEcCtD
Goserelin—Flatulence—Doxorubicin—urinary bladder cancer	5.64e-05	0.000413	CcSEcCtD
Goserelin—Arthralgia—Methotrexate—urinary bladder cancer	5.63e-05	0.000413	CcSEcCtD
Goserelin—Chest pain—Methotrexate—urinary bladder cancer	5.63e-05	0.000413	CcSEcCtD
Goserelin—Myalgia—Methotrexate—urinary bladder cancer	5.63e-05	0.000413	CcSEcCtD
Goserelin—Tension—Doxorubicin—urinary bladder cancer	5.62e-05	0.000412	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	5.59e-05	0.00041	CcSEcCtD
Goserelin—Malaise—Epirubicin—urinary bladder cancer	5.58e-05	0.000409	CcSEcCtD
Goserelin—Discomfort—Methotrexate—urinary bladder cancer	5.56e-05	0.000408	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—urinary bladder cancer	5.56e-05	0.000408	CcSEcCtD
Goserelin—Leukopenia—Epirubicin—urinary bladder cancer	5.54e-05	0.000406	CcSEcCtD
Goserelin—Back pain—Doxorubicin—urinary bladder cancer	5.54e-05	0.000406	CcSEcCtD
Goserelin—Muscle spasms—Doxorubicin—urinary bladder cancer	5.5e-05	0.000403	CcSEcCtD
Goserelin—Palpitations—Epirubicin—urinary bladder cancer	5.47e-05	0.000401	CcSEcCtD
Goserelin—Confusional state—Methotrexate—urinary bladder cancer	5.44e-05	0.000399	CcSEcCtD
Goserelin—Cough—Epirubicin—urinary bladder cancer	5.4e-05	0.000396	CcSEcCtD
Goserelin—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.4e-05	0.000396	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—urinary bladder cancer	5.4e-05	0.000395	CcSEcCtD
Goserelin—Convulsion—Epirubicin—urinary bladder cancer	5.36e-05	0.000393	CcSEcCtD
Goserelin—Infection—Methotrexate—urinary bladder cancer	5.36e-05	0.000393	CcSEcCtD
Goserelin—Nausea—Etoposide—urinary bladder cancer	5.35e-05	0.000392	CcSEcCtD
Goserelin—Hypertension—Epirubicin—urinary bladder cancer	5.34e-05	0.000392	CcSEcCtD
Goserelin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.31e-05	0.000389	CcSEcCtD
Goserelin—Nervous system disorder—Methotrexate—urinary bladder cancer	5.29e-05	0.000388	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—urinary bladder cancer	5.29e-05	0.000388	CcSEcCtD
Goserelin—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.28e-05	0.000387	CcSEcCtD
Goserelin—Chest pain—Epirubicin—urinary bladder cancer	5.27e-05	0.000386	CcSEcCtD
Goserelin—Arthralgia—Epirubicin—urinary bladder cancer	5.27e-05	0.000386	CcSEcCtD
Goserelin—Myalgia—Epirubicin—urinary bladder cancer	5.27e-05	0.000386	CcSEcCtD
Goserelin—Anxiety—Epirubicin—urinary bladder cancer	5.25e-05	0.000385	CcSEcCtD
Goserelin—Skin disorder—Methotrexate—urinary bladder cancer	5.24e-05	0.000384	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.23e-05	0.000383	CcSEcCtD
Goserelin—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.22e-05	0.000382	CcSEcCtD
Goserelin—Discomfort—Epirubicin—urinary bladder cancer	5.21e-05	0.000381	CcSEcCtD
Goserelin—Malaise—Doxorubicin—urinary bladder cancer	5.16e-05	0.000378	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—urinary bladder cancer	5.15e-05	0.000378	CcSEcCtD
Goserelin—Anorexia—Methotrexate—urinary bladder cancer	5.14e-05	0.000377	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—urinary bladder cancer	5.13e-05	0.000376	CcSEcCtD
Goserelin—Confusional state—Epirubicin—urinary bladder cancer	5.09e-05	0.000373	CcSEcCtD
Goserelin—Palpitations—Doxorubicin—urinary bladder cancer	5.06e-05	0.000371	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.05e-05	0.00037	CcSEcCtD
Goserelin—Oedema—Epirubicin—urinary bladder cancer	5.05e-05	0.00037	CcSEcCtD
Goserelin—Hypotension—Methotrexate—urinary bladder cancer	5.04e-05	0.00037	CcSEcCtD
Goserelin—Infection—Epirubicin—urinary bladder cancer	5.02e-05	0.000368	CcSEcCtD
Goserelin—Cough—Doxorubicin—urinary bladder cancer	5e-05	0.000366	CcSEcCtD
Goserelin—Shock—Epirubicin—urinary bladder cancer	4.97e-05	0.000364	CcSEcCtD
Goserelin—Convulsion—Doxorubicin—urinary bladder cancer	4.96e-05	0.000364	CcSEcCtD
Goserelin—Nervous system disorder—Epirubicin—urinary bladder cancer	4.95e-05	0.000363	CcSEcCtD
Goserelin—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.94e-05	0.000362	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—urinary bladder cancer	4.94e-05	0.000362	CcSEcCtD
Goserelin—Tachycardia—Epirubicin—urinary bladder cancer	4.93e-05	0.000361	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.92e-05	0.00036	CcSEcCtD
Goserelin—Skin disorder—Epirubicin—urinary bladder cancer	4.91e-05	0.00036	CcSEcCtD
Goserelin—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.88e-05	0.000358	CcSEcCtD
Goserelin—Insomnia—Methotrexate—urinary bladder cancer	4.88e-05	0.000358	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—urinary bladder cancer	4.87e-05	0.000357	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—urinary bladder cancer	4.87e-05	0.000357	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—urinary bladder cancer	4.87e-05	0.000357	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—urinary bladder cancer	4.86e-05	0.000356	CcSEcCtD
Goserelin—Paraesthesia—Methotrexate—urinary bladder cancer	4.85e-05	0.000355	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.84e-05	0.000355	CcSEcCtD
Goserelin—Discomfort—Doxorubicin—urinary bladder cancer	4.82e-05	0.000353	CcSEcCtD
Goserelin—Anorexia—Epirubicin—urinary bladder cancer	4.81e-05	0.000353	CcSEcCtD
Goserelin—Dyspnoea—Methotrexate—urinary bladder cancer	4.81e-05	0.000353	CcSEcCtD
Goserelin—Somnolence—Methotrexate—urinary bladder cancer	4.8e-05	0.000352	CcSEcCtD
Goserelin—Dry mouth—Doxorubicin—urinary bladder cancer	4.77e-05	0.000349	CcSEcCtD
Goserelin—Dyspepsia—Methotrexate—urinary bladder cancer	4.75e-05	0.000348	CcSEcCtD
Goserelin—Hypotension—Epirubicin—urinary bladder cancer	4.72e-05	0.000346	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—urinary bladder cancer	4.71e-05	0.000345	CcSEcCtD
Goserelin—Decreased appetite—Methotrexate—urinary bladder cancer	4.69e-05	0.000344	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.67e-05	0.000342	CcSEcCtD
Goserelin—Oedema—Doxorubicin—urinary bladder cancer	4.67e-05	0.000342	CcSEcCtD
Goserelin—Fatigue—Methotrexate—urinary bladder cancer	4.65e-05	0.000341	CcSEcCtD
Goserelin—Infection—Doxorubicin—urinary bladder cancer	4.64e-05	0.00034	CcSEcCtD
Goserelin—Pain—Methotrexate—urinary bladder cancer	4.62e-05	0.000338	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.6e-05	0.000337	CcSEcCtD
Goserelin—Shock—Doxorubicin—urinary bladder cancer	4.6e-05	0.000337	CcSEcCtD
Goserelin—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.58e-05	0.000336	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.58e-05	0.000335	CcSEcCtD
Goserelin—Insomnia—Epirubicin—urinary bladder cancer	4.57e-05	0.000335	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—urinary bladder cancer	4.56e-05	0.000334	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—urinary bladder cancer	4.54e-05	0.000333	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—urinary bladder cancer	4.54e-05	0.000332	CcSEcCtD
Goserelin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.52e-05	0.000331	CcSEcCtD
Goserelin—Dyspnoea—Epirubicin—urinary bladder cancer	4.5e-05	0.00033	CcSEcCtD
Goserelin—Somnolence—Epirubicin—urinary bladder cancer	4.49e-05	0.000329	CcSEcCtD
Goserelin—Anorexia—Doxorubicin—urinary bladder cancer	4.45e-05	0.000326	CcSEcCtD
Goserelin—Feeling abnormal—Methotrexate—urinary bladder cancer	4.45e-05	0.000326	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—urinary bladder cancer	4.45e-05	0.000326	CcSEcCtD
Goserelin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.41e-05	0.000323	CcSEcCtD
Goserelin—Decreased appetite—Epirubicin—urinary bladder cancer	4.39e-05	0.000322	CcSEcCtD
Goserelin—Hypotension—Doxorubicin—urinary bladder cancer	4.37e-05	0.00032	CcSEcCtD
Goserelin—Fatigue—Epirubicin—urinary bladder cancer	4.35e-05	0.000319	CcSEcCtD
Goserelin—Pain—Epirubicin—urinary bladder cancer	4.32e-05	0.000317	CcSEcCtD
Goserelin—Constipation—Epirubicin—urinary bladder cancer	4.32e-05	0.000317	CcSEcCtD
Goserelin—Urticaria—Methotrexate—urinary bladder cancer	4.29e-05	0.000314	CcSEcCtD
Goserelin—Abdominal pain—Methotrexate—urinary bladder cancer	4.27e-05	0.000313	CcSEcCtD
Goserelin—Body temperature increased—Methotrexate—urinary bladder cancer	4.27e-05	0.000313	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.26e-05	0.000312	CcSEcCtD
Goserelin—Insomnia—Doxorubicin—urinary bladder cancer	4.23e-05	0.00031	CcSEcCtD
Goserelin—Paraesthesia—Doxorubicin—urinary bladder cancer	4.2e-05	0.000308	CcSEcCtD
Goserelin—Dyspnoea—Doxorubicin—urinary bladder cancer	4.17e-05	0.000305	CcSEcCtD
Goserelin—Feeling abnormal—Epirubicin—urinary bladder cancer	4.16e-05	0.000305	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—urinary bladder cancer	4.15e-05	0.000304	CcSEcCtD
Goserelin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.13e-05	0.000303	CcSEcCtD
Goserelin—Dyspepsia—Doxorubicin—urinary bladder cancer	4.11e-05	0.000301	CcSEcCtD
Goserelin—Decreased appetite—Doxorubicin—urinary bladder cancer	4.06e-05	0.000298	CcSEcCtD
Goserelin—Fatigue—Doxorubicin—urinary bladder cancer	4.03e-05	0.000295	CcSEcCtD
Goserelin—Urticaria—Epirubicin—urinary bladder cancer	4.01e-05	0.000294	CcSEcCtD
Goserelin—Pain—Doxorubicin—urinary bladder cancer	4e-05	0.000293	CcSEcCtD
Goserelin—Constipation—Doxorubicin—urinary bladder cancer	4e-05	0.000293	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—urinary bladder cancer	3.99e-05	0.000293	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—urinary bladder cancer	3.99e-05	0.000293	CcSEcCtD
Goserelin—Hypersensitivity—Methotrexate—urinary bladder cancer	3.98e-05	0.000291	CcSEcCtD
Goserelin—Asthenia—Methotrexate—urinary bladder cancer	3.87e-05	0.000284	CcSEcCtD
Goserelin—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.85e-05	0.000282	CcSEcCtD
Goserelin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.82e-05	0.00028	CcSEcCtD
Goserelin—Pruritus—Methotrexate—urinary bladder cancer	3.82e-05	0.00028	CcSEcCtD
Goserelin—Hypersensitivity—Epirubicin—urinary bladder cancer	3.72e-05	0.000273	CcSEcCtD
Goserelin—Urticaria—Doxorubicin—urinary bladder cancer	3.71e-05	0.000272	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—urinary bladder cancer	3.69e-05	0.000271	CcSEcCtD
Goserelin—Body temperature increased—Doxorubicin—urinary bladder cancer	3.69e-05	0.000271	CcSEcCtD
Goserelin—Diarrhoea—Methotrexate—urinary bladder cancer	3.69e-05	0.000271	CcSEcCtD
Goserelin—Asthenia—Epirubicin—urinary bladder cancer	3.62e-05	0.000266	CcSEcCtD
Goserelin—Pruritus—Epirubicin—urinary bladder cancer	3.57e-05	0.000262	CcSEcCtD
Goserelin—Dizziness—Methotrexate—urinary bladder cancer	3.57e-05	0.000262	CcSEcCtD
Goserelin—Diarrhoea—Epirubicin—urinary bladder cancer	3.46e-05	0.000253	CcSEcCtD
Goserelin—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.44e-05	0.000252	CcSEcCtD
Goserelin—Vomiting—Methotrexate—urinary bladder cancer	3.43e-05	0.000251	CcSEcCtD
Goserelin—Rash—Methotrexate—urinary bladder cancer	3.4e-05	0.000249	CcSEcCtD
Goserelin—Dermatitis—Methotrexate—urinary bladder cancer	3.4e-05	0.000249	CcSEcCtD
Goserelin—Headache—Methotrexate—urinary bladder cancer	3.38e-05	0.000248	CcSEcCtD
Goserelin—Asthenia—Doxorubicin—urinary bladder cancer	3.35e-05	0.000246	CcSEcCtD
Goserelin—Dizziness—Epirubicin—urinary bladder cancer	3.34e-05	0.000245	CcSEcCtD
Goserelin—Pruritus—Doxorubicin—urinary bladder cancer	3.31e-05	0.000242	CcSEcCtD
Goserelin—Vomiting—Epirubicin—urinary bladder cancer	3.21e-05	0.000235	CcSEcCtD
Goserelin—Nausea—Methotrexate—urinary bladder cancer	3.21e-05	0.000235	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—urinary bladder cancer	3.2e-05	0.000234	CcSEcCtD
Goserelin—Rash—Epirubicin—urinary bladder cancer	3.18e-05	0.000233	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—urinary bladder cancer	3.18e-05	0.000233	CcSEcCtD
Goserelin—Headache—Epirubicin—urinary bladder cancer	3.16e-05	0.000232	CcSEcCtD
Goserelin—Dizziness—Doxorubicin—urinary bladder cancer	3.09e-05	0.000226	CcSEcCtD
Goserelin—Nausea—Epirubicin—urinary bladder cancer	3e-05	0.00022	CcSEcCtD
Goserelin—Vomiting—Doxorubicin—urinary bladder cancer	2.97e-05	0.000218	CcSEcCtD
Goserelin—Rash—Doxorubicin—urinary bladder cancer	2.95e-05	0.000216	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—urinary bladder cancer	2.94e-05	0.000216	CcSEcCtD
Goserelin—Headache—Doxorubicin—urinary bladder cancer	2.93e-05	0.000215	CcSEcCtD
Goserelin—Nausea—Doxorubicin—urinary bladder cancer	2.78e-05	0.000203	CcSEcCtD
